GSTM2

Summary

GSTM2 (glutathione S-transferase mu 2, HGNC:4634) is a protein-coding gene on chromosome 1p13.3, encoding Glutathione S-transferase Mu 2 (P28161). Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.

Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase that belongs to the mu class. The mu class of enzymes functions in the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with glutathione. The genes encoding the mu class of enzymes are organized in a gene cluster on chromosome 1p13.3 and are known to be highly polymorphic. These genetic variations can change an individual’s susceptibility to carcinogens and toxins as well as affect the toxicity and efficacy of certain drugs.

Source: NCBI Gene 2946 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 28 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000848

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4634
Approved symbol	GSTM2
Name	glutathione S-transferase mu 2
Location	1p13.3
Locus type	gene with protein product
Status	Approved
Aliases	GST4
Ensembl gene	ENSG00000213366
Ensembl biotype	protein_coding
OMIM	138380
Entrez	2946

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 15 protein_coding, 5 retained_intron, 1 protein_coding_CDS_not_defined, 1 TEC

ENST00000241337, ENST00000369827, ENST00000369829, ENST00000369831, ENST00000414179, ENST00000442650, ENST00000460717, ENST00000464206, ENST00000467579, ENST00000472225, ENST00000476040, ENST00000481656, ENST00000496578, ENST00000568786, ENST00000624726, ENST00000864527, ENST00000864528, ENST00000864529, ENST00000864530, ENST00000918996, ENST00000942832, ENST00000942833

RefSeq mRNA: 2 — MANE Select: NM_000848 NM_000848, NM_001142368

CCDS: CCDS44192, CCDS808

Canonical transcript exons

ENST00000241337 — 8 exons

Exon	Start	End
ENSE00001826241	109674747	109675286
ENSE00002597187	109668057	109668151
ENSE00003475300	109669290	109669371
ENSE00003480674	109671287	109671382
ENSE00003521639	109668425	109668500
ENSE00003538721	109669471	109669571
ENSE00003549375	109671473	109671583
ENSE00003560039	109668925	109668989

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 99.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.1047 / max 476.4681, expressed in 1527 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4443	38.1928	1525
4442	0.6878	389
4444	0.2242	108

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ovary	UBERON:0002119	99.49	gold quality
right uterine tube	UBERON:0001302	99.40	gold quality
right ovary	UBERON:0002118	99.40	gold quality
fundus of stomach	UBERON:0001160	99.25	gold quality
pituitary gland	UBERON:0000007	99.14	gold quality
ovary	UBERON:0000992	99.10	gold quality
tibial nerve	UBERON:0001323	99.08	gold quality
vagina	UBERON:0000996	99.07	gold quality
adenohypophysis	UBERON:0002196	99.05	gold quality
prostate gland	UBERON:0002367	98.98	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.95	gold quality
endocervix	UBERON:0000458	98.90	gold quality
skin of abdomen	UBERON:0001416	98.88	gold quality
body of uterus	UBERON:0009853	98.87	gold quality
left uterine tube	UBERON:0001303	98.85	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.82	gold quality
mucosa of stomach	UBERON:0001199	98.81	gold quality
fallopian tube	UBERON:0003889	98.80	gold quality
nucleus accumbens	UBERON:0001882	98.78	gold quality
left lobe of thyroid gland	UBERON:0001120	98.76	gold quality
caudate nucleus	UBERON:0001873	98.70	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.67	gold quality
zone of skin	UBERON:0000014	98.66	gold quality
lower esophagus	UBERON:0013473	98.66	gold quality
body of stomach	UBERON:0001161	98.65	gold quality
thyroid gland	UBERON:0002046	98.65	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.59	gold quality
putamen	UBERON:0001874	98.58	gold quality
skin of leg	UBERON:0001511	98.52	gold quality
lower esophagus mucosa	UBERON:0035834	98.47	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.51

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): DNMT3B, NFE2L2, PGR, SP1

miRNA regulators (miRDB)

29 targeting GSTM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-3188	98.58	65.60	878
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-30C-1-3P	97.80	66.36	1499
HSA-MIR-30C-2-3P	97.80	66.45	1499
HSA-MIR-6788-5P	97.80	66.41	1532
HSA-MIR-3126-5P	96.87	65.83	912
HSA-MIR-6875-5P	96.87	65.49	958
HSA-MIR-4278	95.28	65.49	351
HSA-MIR-2861	95.24	65.47	1056

Literature-anchored findings (GeneRIF, showing 23)

• identification of residues capable of driving functional diversification in evolution (PMID:12486119)
• dinitrosyl-diglutathionyl-iron complex, a natural carrier of nitric oxide, binds with extraordinary affinity to GSTA1-1, which is explained by molecular modeling and related to molecular evolution (PMID:12871945)
• GST-M2 may play an important future role in lowering the incidence of benzo[a]pyrene-diolepoxide-induced DNA damage. (PMID:15725629)
• CVD risk was higher in smokers compared to non-smokers with GSTT1-1. No significant associations were observed by GSTM1. (PMID:16002077)
• dinitrosyl-diglutathionyl-iron complex bound to Alpha class glutathione S-transferases with extraordinary high affinity in hepatocytes (PMID:17197702)
• A significant association was found between oxidative stress GSTM1 deletion and the HMOX-1 long repeat and heart rate variation in response to particulate air pollution. (PMID:18007994)
• hGSTM2-2 modifies both cardiac & skeletal ryanodine receptor (RyR) activity when it binds to luminal domain of RyR channel complex. GSTM2-2 can interact with specific luminal sites on RyR complex & interaction is likely to be within pore of RyR channel. (PMID:18308613)
• children with variants in GSTM2 (glutathione S-transferase mu 2) were more susceptible to effects of in utero tobacco smoke exposure on lung function (PMID:19151192)
• The active center of GSTM2-2 for inhibition of cardiac ryanodine receptors involves the helix6 sequence and is essential for its efficacy. (PMID:19168034)
• it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility. (PMID:19859803)
• The structure of helix 6 in the carboxyl-terminal fold is critical to GSTM2-2’s inhibitory action on the cardiac ryanodine receptor. (PMID:20417188)
• GST-M2 exhibited high frequency of promoter hypermethylation in lung cancer cells, CpG hypermethylation abated Sp1 binding to the GST-M2 promoter in lung cancer (PMID:21246532)
• High GSTM2 is associated with mesenchymal stem-like cells derived from ovarian teratoma. (PMID:21268265)
• analysis of active-site residues and modulation of catalytic functions in GST-M2 (PMID:21454564)
• it was noted that the alpha-6 helix of GST-C plays a stabilising role in the fold of this domain. By destabilising the conformation of GST-C, an increase in cell translocation efficiency of up to approximately 2-fold was observed. (PMID:21455499)
• High expression of GSTM1 and GSTM4, along with increased endogenous reduced glutathione levels, help to maintain a more reduced state of cytochrome c which decreases apoptosis thus contributing to methotrexate resistance in human MCF7 breast cancer cells. (PMID:23675469)
• the absence of GSTM1 activity can be compensated for by the overexpression of GSTM2. (PMID:24048194)
• demonstrated that the GSTM1 and GSTT1 null genotype may be associated with an increased risk of Hepatocellular carcinoma (HCC) and that individuals having the combination of both defective GST genotypes may be more susceptible to developing HCC (PMID:24399650)
• The absence of GSTM1 and GSTT1 genes increases the risk of lung cancer because of radon exposure. (PMID:24852519)
• the methylation status of CpG sites in GFRA1 and GSTM2 may have a role and could be used as potential biomarkers for the screening of rectal cancer (PMID:27566576)
• Small Extracellular Vesicles Have GST Activity and Ameliorate Senescence-Related Tissue Damage. (PMID:32574561)
• Cellular Trafficking of Glutathione Transferase M2-2 Between U373MG and SHSY-S7 Cells is Mediated by Exosomes. (PMID:33555546)
• GSTM2 is a key molecular determinant of resistance to SG-ARIs. (PMID:36038661)

Cross-species orthologs

43 orthologs

Organism	Symbol	Gene ID
danio_rerio	gstp1.1	ENSDARG00000103019
mus_musculus	Gstm7	ENSMUSG00000004035
rattus_norvegicus	Gstm2	ENSRNOG00000018937
caenorhabditis_elegans		WBGENE00001749
caenorhabditis_elegans		WBGENE00001750
caenorhabditis_elegans		WBGENE00001751
caenorhabditis_elegans		WBGENE00001752
caenorhabditis_elegans		WBGENE00001753
caenorhabditis_elegans		WBGENE00001754
caenorhabditis_elegans		WBGENE00001755
caenorhabditis_elegans		WBGENE00001756
caenorhabditis_elegans		WBGENE00001757
caenorhabditis_elegans		WBGENE00001758
caenorhabditis_elegans		WBGENE00001759
caenorhabditis_elegans		WBGENE00001760
caenorhabditis_elegans		WBGENE00001761
caenorhabditis_elegans		WBGENE00001762
caenorhabditis_elegans		WBGENE00001764
caenorhabditis_elegans		WBGENE00001765
caenorhabditis_elegans		WBGENE00001766
caenorhabditis_elegans		WBGENE00001767
caenorhabditis_elegans		WBGENE00001769
caenorhabditis_elegans		WBGENE00001770
caenorhabditis_elegans		WBGENE00001771
caenorhabditis_elegans		WBGENE00001772
caenorhabditis_elegans	gst-25	WBGENE00001773
caenorhabditis_elegans		WBGENE00001774
caenorhabditis_elegans		WBGENE00001775
caenorhabditis_elegans		WBGENE00001776
caenorhabditis_elegans		WBGENE00001777
caenorhabditis_elegans		WBGENE00001779
caenorhabditis_elegans		WBGENE00001780
caenorhabditis_elegans		WBGENE00001781
caenorhabditis_elegans		WBGENE00001782
caenorhabditis_elegans		WBGENE00001783
caenorhabditis_elegans		WBGENE00001785
caenorhabditis_elegans		WBGENE00001786
caenorhabditis_elegans		WBGENE00001787
caenorhabditis_elegans		WBGENE00001789
caenorhabditis_elegans		WBGENE00018911
caenorhabditis_elegans		WBGENE00018912
caenorhabditis_elegans	W10C8.4	WBGENE00021127
caenorhabditis_elegans		WBGENE00021566

Paralogs (11): GSTP1 (ENSG00000084207), GSTM1 (ENSG00000134184), GSTM5 (ENSG00000134201), GSTM3 (ENSG00000134202), HPGDS (ENSG00000163106), GSTM4 (ENSG00000168765), GSTA4 (ENSG00000170899), GSTA3 (ENSG00000174156), GSTA5 (ENSG00000182793), GSTA1 (ENSG00000243955), GSTA2 (ENSG00000244067)

Protein

Protein identifiers

Glutathione S-transferase Mu 2 — P28161 (reviewed: P28161)

Alternative names: GST class-mu 2, GSTM2-2

All UniProt accessions (7): A0A384P5E9, E9PGV1, E9PHN6, E9PHN7, E9PLF1, P28161, F6XZQ7

UniProt curated annotations — full annotation on UniProt →

Function. Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Participates in the formation of novel hepoxilin regioisomers.

Subunit / interactions. Homodimer.

Subcellular location. Cytoplasm.

Tissue specificity. Muscle.

Similarity. Belongs to the GST superfamily. Mu family.

Isoforms (2)

UniProt ID	Names	Canonical?
P28161-1	1	yes
P28161-2	2

RefSeq proteins (2): NP_000839, NP_001135840 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003081	GST_mu	Family
IPR004045	Glutathione_S-Trfase_N	Domain
IPR004046	GST_C	Domain
IPR010987	Glutathione-S-Trfase_C-like	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR036282	Glutathione-S-Trfase_C_sf	Homologous_superfamily
IPR040079	Glutathione_S-Trfase	Family
IPR050213	GST_superfamily	Family

Pfam: PF00043, PF02798

Enzyme classification (BRENDA):

• EC 2.5.1.18 — glutathione transferase (BRENDA: 178 organisms, 548 substrates, 680 inhibitors, 878 Km, 525 kcat entries)

Substrate kinetics (BRENDA)

79 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
1-CHLORO-2,4-DINITROBENZENE	0.0003–223.6	289
GLUTATHIONE	0.0002–532.43	253
GSH	0.0003–37.4	62
REDUCED GLUTATHIONE	0.017–11.4	24
ETHACRYNIC ACID	0.0001–2.43	19
CUMENE HYDROPEROXIDE	0.038–14.3	10
(+)-2-BROMO-3-(4-NITROPHENYL)PROPANOIC ACID	0.023–0.417	8
MONOCHLOROBIMANE	0.004–0.25	8
4-CHLORO-7-NITROBENZO-2-OXA-1,3-DIAZOLE	0.324–3.866	7
1-IODOHEXANE	0.009–0.059	6
ALACHLOR	0.042–7.23	6
PHENETHYL ISOTHIOCYANATE	0.0065–0.14	6
STYRENE 7,8-OXIDE	0.064–0.365	6
1,2-DICHLORO-4-NITROBENZENE	0.27–1.4	5
1-CHLORO-2,3-DINITROBENZOATE	0.21–20.7	5

Catalyzed reactions (Rhea), 2 shown:

• RX + glutathione = an S-substituted glutathione + a halide anion + H(+) (RHEA:16437)
• 11(S)-hydroxy-14(S),15(S)-epoxy-(5Z,8Z,12E)-eicosatrienoate + glutathione = (11S,15S)-dihydroxy-14(R)-S-glutathionyl-(5Z,8Z,12E)-eicosatrienoate (RHEA:50260)

UniProt features (39 total): helix 9, strand 8, binding site 6, turn 4, sequence conflict 3, domain 2, modified residue 2, chain 1, splice variant 1, sequence variant 1, mutagenesis site 1, site 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
2C4J	X-RAY DIFFRACTION	1.35
5HWL	X-RAY DIFFRACTION	1.6
1XW5	X-RAY DIFFRACTION	1.8
1HNA	X-RAY DIFFRACTION	1.85
1YKC	X-RAY DIFFRACTION	2.1
2AB6	X-RAY DIFFRACTION	2.5
3GUR	X-RAY DIFFRACTION	2.5
2GTU	X-RAY DIFFRACTION	2.55
3GTU	X-RAY DIFFRACTION	2.8
1HNC	X-RAY DIFFRACTION	3
1HNB	X-RAY DIFFRACTION	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P28161-F1	98.53	1.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 210 (important for substrate specificity)

Ligand- & substrate-binding residues (6): 7–8; 43–46; 50; 59–60; 72–73; 116

Post-translational modifications (2): 27, 44

Mutagenesis-validated functional residues (1):

Position	Phenotype
210	reduced enzyme activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-156590	Glutathione conjugation

MSigDB gene sets: 217 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_BIOLOGICAL_OXIDATIONS, GOBP_CIRCULATORY_SYSTEM_PROCESS, GNF2_GSTM1, GNF2_HPN, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_RELAXATION_OF_CARDIAC_MUSCLE, GOBP_MULTICELLULAR_ORGANISMAL_MOVEMENT, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_SKELETAL_MUSCLE_CONTRACTION, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_CARDIAC_MUSCLE_CONTRACTION_BY_REGULATION_OF_THE_RELEASE_OF_SEQUESTERED_CALCIUM_ION, GOMF_GLUTATHIONE_TRANSFERASE_ACTIVITY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_STRIATED_MUSCLE_CONTRACTION

GO Biological Process (13): glutathione metabolic process (GO:0006749), regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880), regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion (GO:0010881), regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion (GO:0014809), nitrobenzene metabolic process (GO:0018916), xenobiotic catabolic process (GO:0042178), linoleic acid metabolic process (GO:0043651), hepoxilin biosynthetic process (GO:0051122), relaxation of cardiac muscle (GO:0055119), cellular detoxification of nitrogen compound (GO:0070458), cellular response to caffeine (GO:0071313), lipid metabolic process (GO:0006629), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (11): glutathione transferase activity (GO:0004364), glutathione peroxidase activity (GO:0004602), fatty acid binding (GO:0005504), calcium channel inhibitor activity (GO:0019855), enzyme binding (GO:0019899), protein homodimerization activity (GO:0042803), glutathione binding (GO:0043295), transmembrane transporter binding (GO:0044325), protein binding (GO:0005515), transferase activity (GO:0016740), identical protein binding (GO:0042802)

GO Cellular Component (4): cytoplasm (GO:0005737), cytosol (GO:0005829), sarcoplasmic reticulum (GO:0016529), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Phase II - Conjugation of compounds	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	3
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	2
cellular detoxification	2
cellular anatomical structure	2
modified amino acid metabolic process	1
sulfur compound metabolic process	1
release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	1
regulation of release of sequestered calcium ion into cytosol	1
regulation of cardiac muscle contraction by calcium ion signaling	1
regulation of skeletal muscle contraction by calcium ion signaling	1
benzene-containing compound metabolic process	1
xenobiotic metabolic process	1
catabolic process	1
long-chain fatty acid metabolic process	1
unsaturated fatty acid metabolic process	1
olefinic compound metabolic process	1
long-chain fatty acid biosynthetic process	1
relaxation of muscle	1
cellular response to stress	1
detoxification of nitrogen compound	1
response to caffeine	1
cellular response to alkaloid	1
cellular response to purine-containing compound	1
primary metabolic process	1
transferase activity, transferring alkyl or aryl (other than methyl) groups	1
peroxidase activity	1
lipid binding	1
monocarboxylic acid binding	1
calcium channel regulator activity	1
calcium channel activity	1
ion channel inhibitor activity	1
identical protein binding	1
protein dimerization activity	1
anion binding	1
modified amino acid binding	1
oligopeptide binding	1
sulfur compound binding	1
binding	1
catalytic activity	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

986 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GSTM2	SLCO6A1	Q86UG4	892
GSTM2	GSTZ1	O43708	838
GSTM2	AP5M1	Q9H0R1	693
GSTM2	GSTA4	O15217	672
GSTM2	GSTT2B	P0CG30	669
GSTM2	GSTO1	P78417	632
GSTM2	PCLAF	Q15004	609
GSTM2	MGST3	O14880	604
GSTM2	DCAF11	Q8TEB1	572
GSTM2	GSTO2	Q9H4Y5	566
GSTM2	NQO1	P15559	547
GSTM2	MOGS	Q13724	543
GSTM2	GSTK1	Q9Y2Q3	540
GSTM2	MGST1	P10620	532
GSTM2	HHAT	Q5VTY9	507
GSTM2	FAM13C	Q8NE31	507

IntAct

17 interactions, top by confidence:

A	B	Type	Score
GSTM2	GSTM5	psi-mi:“MI:0915”(physical association)	0.740
GSTM2	GSTM3	psi-mi:“MI:0914”(association)	0.530
GSTM3	GSTM2	psi-mi:“MI:0914”(association)	0.530
		psi-mi:“MI:0914”(association)	0.350
SAR1B	UBA6	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
GSTM5	GSTM1	psi-mi:“MI:0914”(association)	0.350
GSTM2	GSTM1	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
GSTM5	GSTM2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (31): GSTM3 (Affinity Capture-MS), GSTM5 (Affinity Capture-MS), GSTM4 (Affinity Capture-MS), GSTM2 (Reconstituted Complex), GSTM5 (Affinity Capture-MS), GSTM4 (Affinity Capture-MS), GSTM3 (Affinity Capture-MS), GSTM2 (Affinity Capture-MS), GSTM2 (Affinity Capture-MS), GSTM2 (Affinity Capture-MS), GSTM2 (Two-hybrid), GSTM2 (Affinity Capture-RNA), GSTM4 (Affinity Capture-MS), GSTM5 (Affinity Capture-MS), GSTM3 (Affinity Capture-MS)

ESM2 similar proteins: A0A1W2PR19, A6QQZ0, O09131, O65857, O76483, O88741, P09488, P0CG29, P0CG30, P21266, P28161, P28342, P30109, P30568, P30713, P42760, P46409, P46430, P46439, P46440, P48774, P57108, P78417, Q01579, Q03013, Q03425, Q03662, Q4V8E6, Q5BK56, Q5R8E8, Q61133, Q64471, Q84TK0, Q8R5I6, Q8TB36, Q9BEA9, Q9BEB0, Q9C6C8, Q9D4P7, Q9FE46

Diamond homologs: M1RIR6, O35543, O35660, P00502, P04905, P08009, P08010, P08515, P09488, P10649, P15626, P15964, P16413, P19639, P20136, P21266, P28161, P30112, P30116, P31670, P31671, P35661, P46409, P46419, P46427, P46436, P46439, P48774, P51781, P56598, P86214, Q00285, Q03013, Q5BK56, Q5R8E8, Q80W21, Q8JFZ2, Q8R5I6, Q9BEA9, Q9BEB0

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DNMT3B	“down-regulates quantity by repression”	GSTM2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2941 predictions. Top by Δscore:

Variant	Effect	Δscore
1:109668990:G:GG	donor_gain	1.0000
1:109669284:A:AG	acceptor_gain	1.0000
1:109669285:T:G	acceptor_gain	1.0000
1:109669285:TCCA:T	acceptor_loss	1.0000
1:109669287:CAGCT:C	acceptor_loss	1.0000
1:109669288:A:AG	acceptor_gain	1.0000
1:109669288:A:C	acceptor_loss	1.0000
1:109669289:G:GT	acceptor_gain	1.0000
1:109669289:GC:G	acceptor_gain	1.0000
1:109669289:GCT:G	acceptor_gain	1.0000
1:109669289:GCTGC:G	acceptor_gain	1.0000
1:109669367:CCTGT:C	donor_gain	1.0000
1:109669368:CTGT:C	donor_gain	1.0000
1:109669370:GT:G	donor_gain	1.0000
1:109669371:TG:T	donor_loss	1.0000
1:109669372:G:A	donor_loss	1.0000
1:109669372:G:GG	donor_gain	1.0000
1:109669373:T:TC	donor_loss	1.0000
1:109669374:GAGTA:G	donor_loss	1.0000
1:109669375:AGT:A	donor_loss	1.0000
1:109669572:G:GG	donor_gain	1.0000
1:109688671:A:AG	acceptor_gain	1.0000
1:109688672:G:GG	acceptor_gain	1.0000
1:109688738:G:GG	donor_gain	1.0000
1:109689125:CCTGT:C	donor_gain	1.0000
1:109689126:CTGT:C	donor_gain	1.0000
1:109689128:GT:G	donor_gain	1.0000
1:109689130:G:GG	donor_gain	1.0000
1:109689130:GT:G	donor_loss	1.0000
1:109689131:T:TG	donor_loss	1.0000

AlphaMissense

1453 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:109668948:T:A	W46R	0.995
1:109668948:T:C	W46R	0.995
1:109668137:T:A	W8R	0.992
1:109668137:T:C	W8R	0.992
1:109668134:T:C	Y7H	0.991
1:109668149:G:A	G12R	0.991
1:109668149:G:C	G12R	0.991
1:109668139:G:C	W8C	0.990
1:109668139:G:T	W8C	0.990
1:109669293:C:T	P61S	0.990
1:109669354:C:A	A81D	0.990
1:109668950:G:C	W46C	0.989
1:109668950:G:T	W46C	0.989
1:109669291:T:C	L60P	0.989
1:109669329:A:C	S73R	0.989
1:109669331:C:A	S73R	0.989
1:109669331:C:G	S73R	0.989
1:109669357:G:C	R82P	0.989
1:109669294:C:A	P61H	0.988
1:109671485:G:C	D157H	0.988
1:109668149:G:T	G12W	0.987
1:109671488:T:C	F158L	0.987
1:109671490:C:A	F158L	0.987
1:109671490:C:G	F158L	0.987
1:109668150:G:A	G12E	0.986
1:109668131:G:T	G6W	0.985
1:109668949:G:C	W46S	0.985
1:109668981:T:C	F57L	0.985
1:109668983:T:A	F57L	0.985
1:109668983:T:G	F57L	0.985

dbSNP variants (sampled 300 via entrez): RS1000072383 (1:109677533 G>A), RS1000866694 (1:109676430 C>A), RS1000933050 (1:109669443 TGA>T), RS1001479157 (1:109679190 G>A), RS1001652092 (1:109673371 G>C), RS1001783199 (1:109679055 T>C), RS1002144305 (1:109666159 C>T), RS1002486044 (1:109668224 G>T), RS1002818452 (1:109669072 A>C), RS1003147829 (1:109680475 G>A,C), RS1003302346 (1:109674073 G>A,C,T), RS1003457220 (1:109680215 T>C), RS1004116021 (1:109674434 G>C), RS1004267076 (1:109668213 G>C), RS1004409118 (1:109674035 C>T)

Disease associations

OMIM: gene MIM:138380 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST009698_116	Metabolite levels	9.000000e-13
GCST009733_206	Urinary metabolite levels in chronic kidney disease	8.000000e-16
GCST009733_56	Urinary metabolite levels in chronic kidney disease	7.000000e-86
GCST010241_172	Apolipoprotein A1 levels	3.000000e-59
GCST010242_530	HDL cholesterol levels	6.000000e-48
GCST010243_6	Apolipoprotein B levels	4.000000e-14
GCST010245_73	LDL cholesterol levels	6.000000e-10

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0005059	acylcarnitine measurement
EFO:0005116	urinary metabolite measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004611	low density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4589 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 93,882 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL140	CURCUMIN	3	93,882

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

65 potent at pChembl≥5 of 72 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.52	IC50	3	nM	CHEMBL3360522
8.30	IC50	5	nM	CHEMBL3360529
8.30	IC50	5	nM	CHEMBL3360531
8.22	IC50	6	nM	CHEMBL3352898
8.22	IC50	6	nM	CHEMBL3360535
8.15	IC50	7	nM	CHEMBL3360521
8.10	IC50	8	nM	CHEMBL3360530
8.00	IC50	10	nM	CHEMBL1234570
8.00	IC50	10	nM	CHEMBL3360505
8.00	IC50	10	nM	CHEMBL3360518
7.70	IC50	20	nM	CHEMBL2430532
7.70	IC50	20	nM	CHEMBL3360504
7.70	IC50	20	nM	CHEMBL3360515
7.70	IC50	20	nM	CHEMBL3360519
7.70	IC50	20	nM	CHEMBL3360520
7.70	IC50	20	nM	CHEMBL1234570
7.52	IC50	30	nM	CHEMBL3360523
7.52	IC50	30	nM	CHEMBL3360524
7.52	IC50	30	nM	CHEMBL3360528
7.52	IC50	30	nM	CHEMBL3360534
7.40	IC50	40	nM	CHEMBL2430537
7.40	IC50	40	nM	CHEMBL3360527
7.40	IC50	40	nM	CHEMBL3360532
7.30	IC50	50	nM	CHEMBL3360511
7.22	IC50	60	nM	CHEMBL3360526
7.16	IC50	70	nM	CHEMBL3360525
7.16	IC50	70	nM	CHEMBL3360533
7.10	IC50	80	nM	CHEMBL3360507
7.05	IC50	90	nM	CHEMBL4757112
7.05	IC50	90	nM	CHEMBL4757438
7.00	IC50	100	nM	CHEMBL4742105
7.00	IC50	100	nM	CHEMBL5289652
6.96	IC50	110	nM	CHEMBL4794932
6.89	IC50	130	nM	CHEMBL3360513
6.89	IC50	130	nM	CHEMBL4777228
6.85	IC50	140	nM	CHEMBL3360509
6.80	IC50	160	nM	CHEMBL4764480
6.80	IC50	160	nM	CHEMBL4748062
6.77	IC50	170	nM	CHEMBL4763818
6.72	IC50	190	nM	CHEMBL3360512
6.70	IC50	200	nM	CHEMBL3360510
6.70	IC50	200	nM	CHEMBL4797471
6.64	IC50	230	nM	CHEMBL3360508
6.55	IC50	280	nM	CHEMBL4783291
6.52	IC50	300	nM	CHEMBL3360514
6.50	IC50	320	nM	CHEMBL4743365
6.48	IC50	330	nM	CHEMBL4762005
6.46	IC50	350	nM	CHEMBL4787180
6.44	IC50	360	nM	CHEMBL4763865
6.41	IC50	390	nM	CHEMBL4762497

PubChem BioAssay actives

66 with measured affinity, of 80 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanylmethyl]-N-phenylmethoxybenzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0030	uM
methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]propanoate	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0050	uM
4-(cyclohexylmethylsulfanyl)-7-nitro-2,1,3-benzoxadiazole	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0050	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanylmethyl]benzoic acid	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0060	uM
8-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]octan-1-ol	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0060	uM
ethyl 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanylmethyl]benzoate	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0070	uM
methyl 3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-2-(phenylmethoxycarbonylamino)propanoate	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0080	uM
7-nitro-4-(3-phenylpropylsulfanyl)-2,1,3-benzoxadiazole	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0100	uM
2-[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]phenyl]acetic acid	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0100	uM
6-[(4-nitro-6,7-dihydro-2,1,3-benzoxadiazol-7-yl)sulfanyl]hexan-1-ol	1933415: Inhibition of human GSTM2-2 expressed in Escherichia coli assessed as inhibition by fluorescence based analysis	ic50	0.0100	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexan-1-ol	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0100	uM
7-nitro-4-(2-phenylethylsulfanyl)-2,1,3-benzoxadiazole	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0200	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-N-phenylmethoxybenzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0200	uM
3-[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]phenyl]propanoic acid	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0200	uM
3-[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]phenyl]-N-phenylmethoxypropanamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0200	uM
4-benzylsulfanyl-7-nitro-2,1,3-benzoxadiazole	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0200	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]butan-1-ol	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0300	uM
N-methoxy-4-[2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]ethyl]benzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0300	uM
methyl 3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]propanoate	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0300	uM
1-[3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]propanoyl]piperidin-4-one	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0300	uM
1-[2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]ethyl]piperidin-4-one	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0400	uM
4-tert-butylsulfanyl-7-nitro-2,1,3-benzoxadiazole	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0400	uM
7-nitro-4-phenylsulfanyl-2,1,3-benzoxadiazole	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0400	uM
N-hydroxy-4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0500	uM
N-(2-hydroxyethyl)-3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]propanamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0600	uM
N-[2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]ethyl]acetamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0700	uM
3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]propane-1,2-diol	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0700	uM
3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzoic acid	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.0800	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-[3-(dimethylamino)propylamino]-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.0900	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-oxo-4-[4-(trifluoromethyl)anilino]butanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.0900	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(2-morpholin-4-ylethylamino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.1000	uM
2-[2-[2-[(4-nitro-6,7-dihydro-2,1,3-benzoxadiazol-7-yl)sulfanyl]ethoxy]ethoxy]ethanol	1933415: Inhibition of human GSTM2-2 expressed in Escherichia coli assessed as inhibition by fluorescence based analysis	ic50	0.1000	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-oxo-4-piperidin-1-ylbutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.1100	uM
N-methoxy-4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.1300	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(4-methoxyanilino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.1300	uM
ethyl 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzoate	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.1400	uM
4-[6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexoxy]-4-oxobutanoic acid	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.1600	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-[2-(dimethylamino)ethylamino]-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.1600	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-morpholin-4-yl-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.1700	uM
N,N-dimethyl-4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.1900	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.2000	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-oxo-4-(2-pyrrolidin-1-ylethylamino)butanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.2000	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzoic acid	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.2300	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(2-methoxyanilino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.2800	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-N-(oxan-2-yloxy)benzamide	1174248: Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.3000	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(4-fluoroanilino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.3200	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(2-chloroanilino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.3300	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(2-fluoroanilino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.3500	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(3,4-dimethoxyanilino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.3600	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(4-methylanilino)-4-oxobutanoate	1731077: Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.3900	uM

CTD chemical–gene interactions

96 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, affects expression, affects binding, increases reaction, decreases expression	4
Decitabine	affects methylation, affects binding, decreases reaction, decreases expression, increases reaction (+2 more)	4
Benzo(a)pyrene	increases expression, increases methylation, decreases response to substance, affects methylation, decreases expression	4
Butyrates	increases activity, increases expression	3
trichostatin A	decreases reaction, affects methylation, increases reaction, affects expression, decreases expression	2
mercuric bromide	decreases expression, affects cotreatment	2
cylindrospermopsin	decreases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Glutathione	affects metabolic processing, affects cotreatment, increases metabolic processing	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
tert-Butylhydroperoxide	decreases expression	2
bisphenol F	increases expression	1
methylmercuric chloride	decreases expression	1
apocarotenal	decreases expression	1
astaxanthine	affects cotreatment, increases expression	1
kaempferol	affects cotreatment, increases expression	1
bisphenol A	decreases expression	1
titanium dioxide	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
nickel chloride	decreases expression, decreases reaction, affects binding, affects cotreatment, increases reaction (+1 more)	1
ochratoxin A	affects expression	1
4-hydroxy-2-nonenal	decreases response to substance	1
hexylglutathione	decreases activity	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, decreases reaction	1
brequinar	affects expression	1
desethylamodiaquine	affects cotreatment, increases metabolic processing	1
nefazodone	affects cotreatment, decreases expression	1
4-hydroxy-equilenin	decreases expression	1

ChEMBL screening assays

7 unique, capped per target: 5 binding, 2 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1743228	ADMET	Substrates for human cytosolic glutathione transferase GSTM2	Casarett and Doull’s Toxicology The Basic Science of Poisons, 7th edition
CHEMBL3378817	Binding	Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method	Synthesis and structure–activity relationship of new cytotoxic agents targeting human glutathione-S-transferases. — Eur J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SQ70	HAP1 GSTM2 (-) 1	Cancer cell line	Male
CVCL_XP43	HAP1 GSTM2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.